AR060993A1 - Acidos carboxilicos sustituidos con 4,5-difenilpirimidiniloxi o mercapto, procedimiento para su preparacion y su uso como productos farmaceuticos - Google Patents

Acidos carboxilicos sustituidos con 4,5-difenilpirimidiniloxi o mercapto, procedimiento para su preparacion y su uso como productos farmaceuticos

Info

Publication number
AR060993A1
AR060993A1 ARP070102011A ARP070102011A AR060993A1 AR 060993 A1 AR060993 A1 AR 060993A1 AR P070102011 A ARP070102011 A AR P070102011A AR P070102011 A ARP070102011 A AR P070102011A AR 060993 A1 AR060993 A1 AR 060993A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
difenylpirimidinyloxi
mercapto
procedure
Prior art date
Application number
ARP070102011A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR060993A1 publication Critical patent/AR060993A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP070102011A 2006-05-11 2007-05-09 Acidos carboxilicos sustituidos con 4,5-difenilpirimidiniloxi o mercapto, procedimiento para su preparacion y su uso como productos farmaceuticos AR060993A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006021872A DE102006021872B4 (de) 2006-05-11 2006-05-11 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR060993A1 true AR060993A1 (es) 2008-07-30

Family

ID=38283003

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102011A AR060993A1 (es) 2006-05-11 2007-05-09 Acidos carboxilicos sustituidos con 4,5-difenilpirimidiniloxi o mercapto, procedimiento para su preparacion y su uso como productos farmaceuticos

Country Status (16)

Country Link
US (1) US7709494B2 (cg-RX-API-DMAC7.html)
EP (1) EP2024339B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009536626A (cg-RX-API-DMAC7.html)
KR (1) KR20090007413A (cg-RX-API-DMAC7.html)
CN (1) CN101421249A (cg-RX-API-DMAC7.html)
AR (1) AR060993A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007250210B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0711399A2 (cg-RX-API-DMAC7.html)
CA (1) CA2651466A1 (cg-RX-API-DMAC7.html)
DE (1) DE102006021872B4 (cg-RX-API-DMAC7.html)
IL (1) IL195178A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008014208A (cg-RX-API-DMAC7.html)
MY (1) MY148483A (cg-RX-API-DMAC7.html)
NO (1) NO20085064L (cg-RX-API-DMAC7.html)
TW (1) TW200815367A (cg-RX-API-DMAC7.html)
WO (1) WO2007131619A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
JP2011515341A (ja) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
ES2627655T3 (es) 2009-05-19 2017-07-31 Neuroderm Ltd Composiciones para la administración continua de inhibidores de DOPA descarboxilasa
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
BR112013004882A2 (pt) 2010-08-31 2016-05-03 Snu R&Db Foundation utilização de reprogramação fetal de agonista ppar delta
SMT201800145T1 (it) * 2010-11-15 2018-05-02 Neuroderm Ltd Somministrazione continua di l-dopa, di inibitori della dopa decarbossilasi, di inibitori della catecol-o-metil trasferasi e composizioni per essa
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9999674B2 (en) 2012-06-05 2018-06-19 Neuroderm, Ltd. Compositions comprising apomorphine and organic acids and uses thereof
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
WO2015084692A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
HRP20231716T1 (hr) 2014-03-13 2024-03-15 Neuroderm Ltd. Pripravci inhibitora dopa dekarboksilaze
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
CN118084940A (zh) 2018-02-13 2024-05-28 吉利德科学公司 Pd-1/pd-l1抑制剂
AU2019255750B2 (en) 2018-04-19 2021-10-21 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665159B1 (fr) * 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
WO2004029204A2 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
AU2007250210B2 (en) 2011-11-10
CA2651466A1 (en) 2007-11-22
IL195178A0 (en) 2009-08-03
EP2024339A1 (de) 2009-02-18
EP2024339B1 (de) 2013-04-10
DE102006021872B4 (de) 2008-04-17
CN101421249A (zh) 2009-04-29
AU2007250210A1 (en) 2007-11-22
MY148483A (en) 2013-04-30
WO2007131619A1 (de) 2007-11-22
NO20085064L (no) 2009-02-06
BRPI0711399A2 (pt) 2011-11-01
US20090149486A1 (en) 2009-06-11
DE102006021872A1 (de) 2007-12-27
US7709494B2 (en) 2010-05-04
KR20090007413A (ko) 2009-01-16
MX2008014208A (es) 2008-11-14
JP2009536626A (ja) 2009-10-15
TW200815367A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
AR060993A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidiniloxi o mercapto, procedimiento para su preparacion y su uso como productos farmaceuticos
AR060992A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para la preparacion de productos farmaceuticos, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para la reduccion de la glucemia
AR060991A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo y composiciones farmaceuticas que los contienen utilizadas para el tratamiento de la diabetes
AR060990A1 (es) Acidos carboxilicos sustituidos con fenilaminobenzoxazol y composiciones farmaceuticas que los contienen, utilizadas para el tratamiento de la diabetes
ECSP077648A (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
AR061238A1 (es) Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
DOP2019000218A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
AR082444A1 (es) Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
CO6280441A2 (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
AR040474A1 (es) Derivados de tiofenolglicosido, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos
AR035498A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos, su uso en la preparacion de medicamentos, intermediarios para su preparacion y composiciones farmaceuticas que los contienen
ECSP055853A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
AR049393A1 (es) Derivados fluoroglicosidicos de pirazoles con actividad inhibitoria de sglt 1; medicamentos que contienen estos compuestos y el empleo de los mismos en el tratamiento de la diabetes tipo i y tipo ii.
AR075717A1 (es) Compuestos de 3- aril quinazolin -4- ona para combatir plagas de invertebrados
CL2009001059A1 (es) Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
ECSP099476A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
UY27388A1 (es) Nuevos compuestos
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CL2009001240A1 (es) Compuestos derivados del acido l-glutamico y l-glutamina marcados con [f-18]; procedimiento de preparacion; composicion farmaceutica que comprende a los compuestos y su uso como agentes en el diagnostico de tumores.
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CL2008002356A1 (es) Sulfoxidos de piperazina-amida; sus procesos de preparacion; las composiciones farmaceuticas que los contienen; y su uso en el tratamiento de enfermedades que se modulan con agonistas lxr alfa y/o beta.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal